Trails Edge Capital Partners, LP — 13F Holdings & Portfolio

CIK 2077247 · latest 13F-HR filed 2026-05-15

Trails Edge Capital Partners, LP manages $436.5M in 13F-reported U.S. long-equity assets across 27 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PCVX (8.82%), DFTX (7.53%), LBRX (7.45%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 12 new positions, exited 9, added to 5, and trimmed 4.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$436.5M

Long-equity book

Holdings

27

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+12 / −9 / ↑5 / ↓4

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • MIRUM PHARMACEUTICALS INC$28.3M +1123.4%
  • VAXCYTE INC$4.5M +13.1%
  • IMMUNOVANT INC$4.2M +68.5%
  • INVENTIVA SA$2.4M +19.4%
  • INHIBIKASE THERAPEUTICS INC$871.2K +6.9%
Show all 5

Top Trims

  • NURIX THERAPEUTICS INC-$6.0M -18.3%
  • VTV THERAPEUTICS INC-$3.7M -40.1%
  • CAMP4 THERAPEUTICS CORP-$3.6M -29.7%
  • IMMUNOCORE HLDGS PLC-$3.1M -13.1%
Show all 4

New Positions

  • DEFINIUM THERAPEUTICS INC$32.9M
  • REVOLUTION MEDICINES INC$23.8M
  • CYTOKINETICS INC$19.8M
  • SYNDAX PHARMACEUTICALS INC$16.4M
  • 4D MOLECULAR THERAPEUTICS IN$12.1M
Show all 12

Exited Positions

  • ACADIA PHARMACEUTICALS INC$37.9M
  • MIND MEDICINE MINDMED INC$34.4M
  • TYRA BIOSCIENCES INC$18.4M
  • AMICUS THERAPEUTICS INC$14.9M
  • APOGEE THERAPEUTICS INC$14.5M
Show all 9
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 VAXCYTE INC PCVX 92243G108 $38.5M 8.82% 662,470 SH
2 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $32.9M 7.53% 1,738,110 SH
3 LB PHARMACEUTICALS INC LBRX 50180M108 $32.5M 7.45% 1,319,362 SH
4 MIRUM PHARMACEUTICALS INC MIRM 604749101 $30.8M 7.05% 333,312 SH
5 NURIX THERAPEUTICS INC NRIX 67080M103 $27.0M 6.19% 1,743,220 SH
6 XENON PHARMACEUTICALS INC XENE 98420N105 $25.6M 5.86% 440,000 SH
7 REVOLUTION MEDICINES INC RVMD 76155X100 $23.8M 5.46% 245,000 SH
8 ARCUS BIOSCIENCES INC RCUS 03969F109 $22.6M 5.19% 1,047,935 SH
9 IMMUNOCORE HLDGS PLC IMCR 45258D105 $20.6M 4.71% 682,597 SH
10 CYTOKINETICS INC CYTK 23282W605 $19.8M 4.53% 300,000 SH
11 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $16.4M 3.76% 701,821 SH
12 NEUROGENE INC NGNE 64135M105 $15.8M 3.62% 782,787 SH
13 INVENTIVA SA IVA 46124U107 $14.8M 3.38% 2,657,997 SH
14 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $13.5M 3.10% 8,057,345 SH
15 4D MOLECULAR THERAPEUTICS IN FDMT 35104E100 $12.1M 2.78% 1,302,917 SH
16 XENON PHARMACEUTICALS INC Put XENE 98420N105 $11.6M 2.66% 200,000 SH
17 X4 PHARMACEUTICALS INC XFOR 98420X202 $10.6M 2.43% 2,571,478 SH
18 IMMUNOVANT INC IMVT 45258J102 $10.3M 2.36% 414,054 SH
19 DESIGN THERAPEUTICS INC DSGN 25056L103 $9.1M 2.08% 852,013 SH
20 CAMP4 THERAPEUTICS CORP CAMP 13463J101 $8.6M 1.96% 1,939,563 SH
21 MINERVA NEUROSCIENCES INC NERV 603380205 $8.5M 1.96% 1,419,000 SH
22 PROMIS NEUROSCIENCES INC PMN 74346M505 $7.1M 1.62% 557,103 SH
23 SOL-GEL TECHNOLOGIES LTD SLGL M8694L137 $6.8M 1.55% 85,496 SH
24 CENTURY THERAPEUTICS INC IPSC 15673T100 $5.5M 1.27% 2,449,993 SH
25 VTV THERAPEUTICS INC VTVT 918385204 $5.5M 1.27% 139,578 SH
26 SENSEI BIOTHERAPEUTICS INC SNSE 81728A207 $3.9M 0.90% 125,000 SH
27 OPUS GENETICS INC IRD 67577R102 $2.3M 0.52% 500,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $436.5M 27 0002077247-26-000003
2025-12-31 2026-02-17 $404.7M 23 0002077247-26-000002